肿瘤坏死因子拮抗剂治疗克罗恩病内瘘的疗效与安全性
基于2000年1月1日至2017年12月31日GETAID试验数据的回顾性研究,纳入156例因克罗恩病内瘘开始抗TNF治疗的患者。中位随访3.5年,68例(43.6%)接受重大腹部手术,1、3、5年无手术累积概率分别为83%、64%、51%;瘘管愈合累积概率分别为15.4%、32.3%、43.9%。32例(20.5%)发生肠脓肿,4例死于恶性肿瘤,1例在抗TNF治疗开始后3个月死于感染性休克。
要点
- 抗TNF治疗可使近半数克罗恩病内瘘患者延迟或避免手术
- C反应蛋白>18 mg/L、白蛋白<36 g/L、诊断时脓肿及狭窄与需手术独立相关
- 抗TNF治疗可能增加脓毒症相关死亡或胃肠道恶性肿瘤风险
核心结论
- 抗TNF治疗可延迟或避免近半数克罗恩病内瘘患者的手术,但可能增加脓毒症相关死亡或胃肠道恶性肿瘤风险。
研究设计与样本
- 回顾性研究,数据来自GETAID试验,收集2000年1月1日至2017年12月31日的数据。
- 最终分析纳入156例因克罗恩病内瘘开始抗TNF治疗的患者(83例男性;中位病程4.9年)。
- 主要终点为重大腹部手术的发生,次要分析包括随访期间瘘管消失及安全性,采用Kaplan-Meier法进行统计分析。
主要发现
- 中位随访3.5年,68例(43.6%)接受重大腹部手术。
- 1、3、5年无手术累积概率分别为83%、64%、51%。
- C反应蛋白>18 mg/L、白蛋白<36 g/L、瘘诊断时存在脓肿及存在狭窄与需手术独立相关。
- 基于影像学分析的瘘管愈合累积概率在1、3、5年分别为15.4%、32.3%、43.9%。
- 32例(20.5%)发生肠脓肿,4例死于恶性肿瘤(3例肠腺癌),1例在抗TNF治疗开始后3个月死于感染性休克。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Few data are available on the effects of tumor necrosis factor (TNF) antagonist therapy for patients with internal fistulizing Crohn's disease (CD) and there is debate regarding the risk of abscess. We aimed to assess the long-term efficacy and safety of anti-TNF therapy for patients with internal fistulas. METHODS: We performed a retrospective study of data collected from the Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives trial, from January 1, 2000, through December 31, 2017. Our final analysis included 156 patients who began treatment with an anti-TNF agent for CD with internal fistula (83 men; median disease duration, 4.9 y). The primary end point was the onset of a major abdominal surgery. Secondary analysis included disappearance of the fistula tract during follow-up evaluation and safety. The Kaplan-Meier method was used for statistical analysis. RESULTS: After a median follow-up period of 3.5 years, 68 patients (43.6%) underwent a major abdominal surgery. The cumulative probabilities for being surgery-free were 83%, 64%, and 51% at 1, 3, and 5 years, respectively. A concentration of C-reactive protein >18 mg/L, an albumin concentration <36 g/L, the presence of an abscess at the fistula diagnosis, and the presence of a stricture were associated independently with the need for surgery. The cumulative probabilities of fistula healing, based on imaging analyses, were 15.4%, 32.3%, and 43.9% at 1, 3, and 5 years, respectively. Thirty-two patients (20.5%) developed an intestinal abscess and 4 patients died from malignancies (3 intestinal adenocarcinomas). One patient died from septic shock 3 months after initiation of anti-TNF therapy. CONCLUSIONS: In a retrospective analysis of data from a large clinical trial, we found that anti-TNF therapy delays or prevents surgery for almost half of patients with CD and luminal fistulas. However, anti-TNF therapy might increase the risk for sepsis-related death or gastrointestinal malignancies.
引用
- Bouguen G, Huguet A, Amiot A, et al. Efficacy and Safety of Tumor Necrosis Factor Antagonists in Treatment of Internal Fistulizing Crohn's Disease. Clin Gastroenterol Hepatol. 2019. PMID: 31128337. doi:10.1016/j.cgh.2019.05.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。